U.S. Markets closed

Athersys, Inc. (ATHX)


NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.55-0.03 (-1.90%)
At close: 4:00PM EDT
People also watch
CURCYTXPSTIOPXACYCC
  • Nate, are you still short at $1.50?
  • Must be some kind of news leakage out of Japan or perhaps European company has signed on as partner here.....obviously, good news coming imho......
  • IGXT (MC $50 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .A LIFETIME OPPORTUNITY HERE GUYS !!!

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $50 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .GL

    Intelgenx (IGXT)

    MarketCap $50 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.80

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017

    http://www.biotuesdays.com/features/2017/5/11/intelgenx-has-multi-faceted-bd-approach-for-its-oral-films

    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
    www.biotuesdays.com
  • With an announcement regarding a confirmed European partner my guess is that we would see a $3+ pps? With actual stroke trial success I don't think that $100+ is out of the question.
  • Have been waiting for a nice run. this is a small precursor of things to come.
  • This price movement I most certainly enjoy. It definitely will take some time for people to digest the true value behind multistem and it's capabilities. I also think that it is promising the pivotal global Phase 3 trial is going to more than likely be a mirror image of the trial being run in Japan, which only goes on to say they are positive about the design and criteria set forth.
  • Up 7% on increasing volume? Interesting!
  • Up 9% now. Dangerous time to be short. Glad I'm long.
  • On those day when the stock jumps you won't be able to find Nate. He always showed up on the day this stock went down
  • Too much good news just around the corner. Today's price jump says so. I think good news may already be leaking out.
  • Yo Nate, how you doing dog?
  • Biotechs in general had a strong day on the market. This may just have been some renewed interest in covering all bases.
  • You suk Gil, you waste of a load!
  • Can anyone fill me in on when the presentation is? I saw they had a presentation between 6/19-6/22 and also, when should the top-line data from the trial run in Japan be coming out?
  • Nate, is that your 73,000 on the bid to cover? Headed back up soon.
  • Athersys Is Poised To Disrupt The Ischemic Stroke Market
    The only existing FDA approved treatment for ischemic stroke is insufficient to meet patients' needs. Athersys has made considerable clinical progress developin
    seekingalpha.com
  • The Yahoo message board used to be a terrific place to cull actual information about this stock. This new format is worthless and is like a professional wrestling match with nitwits making comments of no substance.
  • Monster MicroCaps SPECIAL ALERT to ATHX shareholders – NWBO $.19 and climbing, just announced $11 million financing with convertible debt payable in 3 years at $0.25, $.50 and $1.00. NWBO expected to release final Phase III Trial results any day from now until mid-July. If results are comparable to preliminary data, shares likely to explode to yield enormous percentage gains. Announcement could be huge because DCVax-L and DCVax Direct are also proven effective against 13 common cancers and has only mild fever as potential side effect. This breakthrough immunotherapy might replace the $100 Billion chemotherapy market.
    https://finance.yahoo.com/news/nwbio-closes-3-convertible-debt-154100683.html

  • Another pump and dump, must be another add on offering in the works to pay managements salary and bonuses
  • Love the speculation. Would love to be the old-timer that just sits and says nothing, but that ain't me. Go ATHX! Too early for manipulation that would come later on the way up, after some big swings. Correct me if I'm wrong - the market has many of times in the past.